2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients

NCT02917720 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

75

Enrollment

NETWORK

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

OTHER: TKI discontinuation
DRUG: nilotinib

Sponsor

European LeukemiaNet

Collaborators

[object Object]
[object Object]